What do systematic reviews say?

Statins plus beta interferon vs interferon beta‐1a

It is very uncertain whether statins plus beta interferon changes number of participants with relapses at 12 months Number of… compared with beta interferon (very low certainty).

• Statins for multiple sclerosis 2011 · Cochrane Headline outcomes only
  RR 1 [0.45, 2.23]
  1 study · 34 participants
  Very low
• Statins for multiple sclerosis 2011 · Cochrane Headline outcomes only
  RR 0.7 [0.36, 1.36]
  1 study · 45 participants
  Very low

Statins plus beta interferon vs interferon beta‐1a

The review found no eligible studies for this question.

• Statins for multiple sclerosis 2011 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Statins plus beta interferon vs interferon beta‐1a

It is very uncertain whether statins plus beta interferon changes number of participants with progression at 24 months Number of… compared with beta interferon (very low certainty).

• Statins for multiple sclerosis 2011 · Cochrane Headline outcomes only
  RR 0.13 [0.01, 2.22]
  1 study · 45 participants
  Very low

Statins plus beta interferon vs interferon beta‐1a

It is very uncertain whether statins plus beta interferon changes number of participants with new T2 or GELs at 12 months Number of… compared with beta interferon (very low certainty).

• Statins for multiple sclerosis 2011 · Cochrane Headline outcomes only
  RR 1 [0.3, 3.36]
  1 study · 34 participants
  Very low

Statins plus beta interferon vs interferon beta‐1a

The review found no eligible studies for this question.

• Statins for multiple sclerosis 2011 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Statins plus beta interferon vs interferon beta‐1a

• Statins for multiple sclerosis 2011 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 387 participants
  Moderate